Introducing RASP: Relapse Assessment In Schizophrenia Patients
Nearly 3.4 million adults, or 1.1% of the U.S. population, have a diagnosis of schizophrenia.1,2 As a chronic, relapsing3 condition, those who have schizophrenia may experience worsening of symptoms, repeat hospital stays,4,5 and a decrease in medication efficacy6 – which may contribute to costly care. Additionally, past relapses may predict an increased risk of future relapses and higher annual mental health care costs.7,8
In this webinar, Heidi Waters, MBA, PhD, Director of Outcomes Management with Otsuka Pharmaceutical Development & Commercialization, Inc., presents a new self-report …
Join PsychU today at no cost for access to this and other premium content!